Image-Based Cytometry in Cell Analysis Market Size, Share, and Trends 2024 to 2034

The global image-based cytometry in cell analysis market size is calculated at USD 3.68 billion in 2025 and is forecasted to reach around USD 8.98 billion by 2034, accelerating at a CAGR of 10.43% from 2025 to 2034. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.

  • Last Updated : March 2025
  • Report Code : 5655
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID-19 Impact on Image-Based Cytometry in Cell Analysis Market 

5.1. COVID-19 Landscape: Image-Based Cytometry in Cell Analysis Industry Impact

5.2. COVID-19  Impact Assessment for the Industry

5.3. COVID-19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Image-Based Cytometry in Cell Analysis Market, By Therapeutic Area

8.1. Image-Based Cytometry in Cell Analysis Market, by Therapeutic Area

8.1.1. Oncology & Immune-oncology

8.1.1.1. Market Revenue and Forecast

8.1.2. Cardiovascular & Metabolic Diseases

8.1.2.1. Market Revenue and Forecast

8.1.3. Immunology

8.1.3.1. Market Revenue and Forecast

8.1.4. Rare Diseases

8.1.4.1. Market Revenue and Forecast

8.1.5. Neurological Diseases

8.1.5.1. Market Revenue and Forecast

8.1.6. Others

8.1.6.1. Market Revenue and Forecast

Chapter 9. Global Image-Based Cytometry in Cell Analysis Market, By End User

9.1. Image-Based Cytometry in Cell Analysis Market, by End User

9.1.1. Biotechnology & Pharmaceutical Companies

9.1.1.1. Market Revenue and Forecast

9.1.2. Academia

9.1.2.1. Market Revenue and Forecast

9.1.3. Contract Research Organizations 

9.1.3.1. Market Revenue and Forecast

9.1.4. Contract Development & Manufacturing Organizations

9.1.4.1. Market Revenue and Forecast

Chapter 10. Global Image-Based Cytometry in Cell Analysis Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Forecast, by Therapeutic Area

10.1.2. Market Revenue and Forecast, by End User

10.1.3. U.S.

10.1.3.1. Market Revenue and Forecast, by Therapeutic Area

10.1.3.2. Market Revenue and Forecast, by End User

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Forecast, by Therapeutic Area

10.1.4.2. Market Revenue and Forecast, by End User

10.2. Europe

10.2.1. Market Revenue and Forecast, by Therapeutic Area

10.2.2. Market Revenue and Forecast, by End User

10.2.3. UK

10.2.3.1. Market Revenue and Forecast, by Therapeutic Area

10.2.3.2. Market Revenue and Forecast, by End User

10.2.4. Germany

10.2.4.1. Market Revenue and Forecast, by Therapeutic Area

10.2.4.2. Market Revenue and Forecast, by End User

10.2.5. France

10.2.5.1. Market Revenue and Forecast, by Therapeutic Area

10.2.5.2. Market Revenue and Forecast, by End User

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Forecast, by Therapeutic Area

10.2.6.2. Market Revenue and Forecast, by End User

10.3. APAC

10.3.1. Market Revenue and Forecast, by Therapeutic Area

10.3.2. Market Revenue and Forecast, by End User

10.3.3. India

10.3.3.1. Market Revenue and Forecast, by Therapeutic Area

10.3.3.2. Market Revenue and Forecast, by End User

10.3.4. China

10.3.4.1. Market Revenue and Forecast, by Therapeutic Area

10.3.4.2. Market Revenue and Forecast, by End User

10.3.5. Japan

10.3.5.1. Market Revenue and Forecast, by Therapeutic Area

10.3.5.2. Market Revenue and Forecast, by End User

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Forecast, by Therapeutic Area

10.3.6.2. Market Revenue and Forecast, by End User

10.4. MEA

10.4.1. Market Revenue and Forecast, by Therapeutic Area

10.4.2. Market Revenue and Forecast, by End User

10.4.3. GCC

10.4.3.1. Market Revenue and Forecast, by Therapeutic Area

10.4.3.2. Market Revenue and Forecast, by End User

10.4.4. North Africa

10.4.4.1. Market Revenue and Forecast, by Therapeutic Area

10.4.4.2. Market Revenue and Forecast, by End User

10.4.5. South Africa

10.4.5.1. Market Revenue and Forecast, by Therapeutic Area

10.4.5.2. Market Revenue and Forecast, by End User

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Forecast, by Therapeutic Area

10.4.6.2. Market Revenue and Forecast, by End User

10.5. Latin America

10.5.1. Market Revenue and Forecast, by Therapeutic Area

10.5.2. Market Revenue and Forecast, by End User

10.5.3. Brazil

10.5.3.1. Market Revenue and Forecast, by Therapeutic Area

10.5.3.2. Market Revenue and Forecast, by End User

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Forecast, by Therapeutic Area

10.5.4.2. Market Revenue and Forecast, by End User

Chapter 11. Company Profiles

11.1. Carl Zeiss Meditec AG

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. Charles River Laboratories

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. Merck KGaA

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. Nanolive SA

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. PerkinElmer, Inc.

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. Sartorius AG

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. Scale Biosciences

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. Thermo Fisher Scientific, Inc.

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. Yokogawa Electric Corporation

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The global image-based cytometry in cell analysis market size is expected to grow from USD 3.33 billion in 2024 to USD 8.98 billion by 2034.

The image-based cytometry in cell analysis market is anticipated to grow at a CAGR of 10.43% between 2025 and 2034.

The major players operating in the image-based cytometry in cell analysis market are Carl Zeiss Meditec AG, Charles River Laboratories, Merck KGaA, Nanolive SA, PerkinElmer, Inc., Sartorius AG, Scale Biosciences, Thermo Fisher Scientific, Inc., Yokogawa Electric Corporation, and Others.

The driving factors of the image-based cytometry in cell analysis market are the rising investments for developing advanced imaging-based cytometers with high-performance capabilities, utilization of various fluorescent dyes and probes for measuring different cell parameters are the factors driving the market growth.

North America region will lead the global image-based cytometry in cell analysis market during the forecast period 2025 to 2034.

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client